Impact BioMedical, Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application … Read more
Impact BioMedical, Inc. (IBO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.225x
Based on the latest financial reports, Impact BioMedical, Inc. (IBO) has a cash flow conversion efficiency ratio of 0.225x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.99 Million) by net assets ($-8.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Impact BioMedical, Inc. - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Impact BioMedical, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Impact BioMedical, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Impact BioMedical, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dalmia Bharat Sugar and Industries Limited
NSE:DALMIASUG
|
0.250x |
|
UPDATER SERVICES LIMITED
NSE:UDS
|
N/A |
|
G50 Corp Ltd
AU:G50
|
-0.061x |
|
China Starch Holdings Limited
PINK:CHNSF
|
N/A |
|
Aquafil S.p.A
OTCQX:ECNLF
|
-0.022x |
|
Right Way Industrial Co Ltd
TW:1506
|
-0.009x |
|
Barem Ambalaj Sanayi ve Ticaret a.s.
IS:BARMA
|
0.232x |
|
Coxon Precise Industrial Co Ltd
TW:3607
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Impact BioMedical, Inc. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Impact BioMedical, Inc. from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.24 Million | $-5.64 Million | -0.779x | -671.98% |
| 2023-12-31 | $28.26 Million | $-2.85 Million | -0.101x | +23.95% |
| 2022-12-31 | $32.67 Million | $-4.33 Million | -0.133x | +87.98% |
| 2021-12-31 | $2.94 Million | $-3.25 Million | -1.104x | -610.22% |
| 2020-12-31 | $-5.28K | $-1.14K | 0.216x | +116.83% |
| 2019-12-31 | $94.89K | $-121.98K | -1.286x | -251.97% |
| 2018-12-31 | $197.12K | $-71.99K | -0.365x | +66.34% |
| 2017-12-31 | $295.22K | $-320.34K | -1.085x | -- |